The effectiveness and safety of exenatide in the treatment of polycystic ovary syndrome: A systematic review and meta-analysis
Abstract
Background Polycystic ovary syndrome (PCOS) is the commonest cause of anovulatory infertility in women of childbearing age. Randomized controlled trials have reported that exenatide and metformin are effective in the treatment of PCOS. In this article, we aim to assess the effectiveness and safety of exenatide/exenatide + metformin in patients suffering from PCOS. Methods Randomized control trials (RCTs) of exenatide therapy were searched through electronic databases. Eligible studies were identi�ed by two reviewers independently. Outcomes were analyzed through Revman 5.4. Results Nine RCTs of 96 studies on 1149 women with PCOS were included to be analyzed, and among the nine RCTs, eight studies compared exenatide with metformin. Our meta-analysis demonstrated that exenatide was more successfully tested in terms of pregnancy rate, menstrual frequency ratio (MFR), sex hormone binding globulin (SHBG), FSH. The reduction in total testosterone (TT), weight, BMI, waist circumference (WC), waist-hip ratio, fasting insulin (FINS) and homeostasis model assessment-insulin resistance (HOMA-IR) were more signi�cant after treatment with exenatide. In terms of safety, exenatide had a lower diarrhea rate, compared with metformin. In the other three studies, exenatide combined with metformin was compared with metformin. Exenatide combined metformin was more effective in improving SHBG, Matsuda index and reducing free androgen index (FAI), Weight and WC. There was no signi�cant difference…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 1,149 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.